Engineering human cardiac stem cells for therapeutic applications in heart disease

工程人类心脏干细胞用于心脏病的治疗应用

• 批准号: 1918802
• 金额: --
• 依托单位: University of Manchester
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-1918802
• 关键词: Engineering; human; cardiac; stem; cells

The heart has minimal regenerative capacity and suffers permanent damage and muscle loss after an infarction. The exogenous use of stem cells to repair the damaged heart has a long history founded on the premise that the transplanted cells might have potent cardiomyogenic potential. As it has emerged that the adult stem cell types being used in fact have very little capacity to make new myocardium1, the very modest benefits achieved by these treatments are no longer surprising. However, in comparison to stem cells of adult origin, human embryonic and induced pluripotent stem cells (hPSCs) have the capacity to make all cell types including bona fide cardiomyocytes and therefore offer much more profound potential for cardiac regenerative medicine. As approximately one billion cardiomyocytes are lost following an infarction, an effective cell therapy may require not only efficient engraftment but also post-transplant expansion potential. Until recently the expansion of hPSC-derived cardiac progenitor cells (CPCs) was unachievable2, but using genetic manipulation this is now possible3. Taking a unique multidisciplinary approach, this project aims to overcome fundamental challenges by engineering cardiac cell identity (epigenetic status/gene expression) as well as the cells' biophysical microenvironment on transplantation, to deliver crucial advances in cardiac regenerative medicine.

心脏具有最小的再生能力，并且在梗塞后遭受永久性损伤和肌肉损失。外源性使用干细胞来修复受损的心脏有着悠久的历史，其前提是移植的细胞可能具有强大的心肌细胞潜能。由于已经发现，正在使用的成体干细胞类型实际上几乎没有能力制造新的心肌1，因此这些治疗所获得的非常有限的益处不再令人惊讶。然而，与成人来源的干细胞相比，人胚胎干细胞和诱导多能干细胞（hPSC）具有制造所有细胞类型的能力，包括真正的心肌细胞，因此为心脏再生医学提供了更深远的潜力。由于梗死后约有10亿个心肌细胞丢失，有效的细胞治疗不仅需要有效的移植，还需要移植后的扩增潜力。直到最近，hPSC衍生的心脏祖细胞（CPC）的扩增是不可复制的2，但使用遗传操作现在是可能的3。该项目采用独特的多学科方法，旨在通过工程心脏细胞身份（表观遗传状态/基因表达）以及移植时细胞的生物物理微环境来克服基本挑战，以实现心脏再生医学的关键进展。